Phosphodiesterase 3 inhibitors boost bone outgrowth

Area of Science:

• Skeletal biology and growth
• Pharmacology
• Cellular signaling

Background:

• C-type natriuretic peptide (CNP) is crucial for skeletal growth, acting on long bone growth plates.
• CNP stimulates calcium (Ca2+) influx via TRPM7 channels in chondrocytes, aiding extracellular matrix synthesis.
• This study investigates stimulating CNP signaling using phosphodiesterase (PDE) inhibitors.

Purpose of the Study:

• To explore the role of PDE3B in growth plates.
• To evaluate the effects of PDE3 inhibitors on skeletal growth.
• To determine if PDE3 inhibitors can stimulate CNP signaling pathways.

Main Methods:

• Gene expression analysis to identify PDE3B's role.
• In vitro studies on growth plate chondrocytes.
• Ex vivo and in vivo analyses of bone and skeletal growth in mice.

Main Results:

• PDE3 inhibitors (cilostazol, milrinone) increased cyclic guanosine monophosphate (cGMP) levels in chondrocytes.
• Inhibitors activated K+ channels, leading to hyperpolarization and enhanced Ca2+ influx via TRPM7.
• Cilostazol promoted bone elongation in vitro and increased body size in juvenile mice.

Conclusions:

• PDE3 inhibitors show potential for treating skeletal disorders associated with short stature.
• Repurposing existing PDE3 inhibitors offers a novel therapeutic strategy for bone growth.
• This research opens new avenues for skeletal disease medication.